-
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
-
Popular APIs of the Year at Pharmasources.com
PharmaSources
December 10, 2024
What are the APIs that caught the highest attention in the year at PharmaSources.com?
-
Global Drug Innovation Trend and Its Market Landscape
Shruti Talashi
September 25, 2024
The creation of novel medications, treatments, and medical equipment that improve patient care and treatment results or outcomes is referred to as pharmaceutical innovation.
-
Research Progress on the Application of Biologics in Pediatric Asthma
Xiaomichong
July 19, 2024
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
-
Common Treatments for Rheumatoid Arthritis
David Orchard-Webb
July 01, 2024
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also impact other systems in the body, including the skin, eyes, lungs, heart, and blood vessels.
-
Introduction of FDA Regulatory Education for Industry (REdI) Annual Conference 2021
Lin Zhang
August 16, 2021
There are many educational events in FDA throughout the year that focus on the pharmaceutical and regulatory industries.
-
Pharmaceutical News of the Week | CPhI.CN - Volumn-based Procurement
PharmaSources/Caicai
August 06, 2020
According to the key content spread on the internet on July 28 regarding the national centralized procurement meeting held on July 24.
-
Eleva and 3PBIOVIAN Sign Strategic GMP Manufacturing and Technology Alliance to Boost Capacity for Eleva’s Platform and Pipeline
PharmaSources
February 05, 2025
Eleva and 3PBIOVIAN sign a strategic GMP manufacturing and technology alliance to boost capacity for Eleva's platform and pipeline.
-
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
PRNewswire
January 31, 2025
Telix completes the acquisition from ImaginAb, getting a drug pipeline and a biologics technology platform.
-
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
prnasia
October 25, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that...